Desfluoro-BMS-694153 (Compound 3) is a calcitonin gene-related peptide receptor (CGRP receptor) antagonist, with a Ki value of 0.01 nM. Desfluoro-BMS-694153 has a significantly reduced risk of CYP3A4 inhibition, and its IC50 values for CYP3A4-BFC and CYP3A4-BZR are 36 and 6 μM respectively. Desfluoro-BMS-694153 can be used for research on migraines.

Deacetoxyvinzolidine (KAR-2) is a bis-indol derivative with high anti-microtubular and anti-tumour activities. Deacetoxyvinzolidine exhibits high affinity for bovine purified brain tubulin (Kd of 3 μM) and inhibits microtubule assembly at a concentration of 10 nM. Deacetoxyvinzolidine does not possess anti-calmodulin activity. Deacetoxyvinzolidine can be used for the study of leukaemia.

DDR1/2 IN-4 (Compound 37) is a selective dual DDR1 and DDR2 kinase inhibitor, with a pKi of 8.6 for DDR1 and a pKi of 8.2 for DDR2. DDR1/2 IN-4 functionally inhibits the kinase activities of DDR1 and DDR2. DDR1/2 IN-4 inhibits the release of MCP-1. DDR1/2 IN-4 can be used in studies related to idiopathic pulmonary fibrosis.

CYP11A1-IN-2 (Compound 61) is a selective cholesterol side-chain cleavage enzyme (CYP11A1) inhibitor. CYP11A1-IN-2 can inhibitor steroid biosynthesis and can be used for the research of steroid hormone-dependent cancers, such as prostate cancer.

Cyclohexane-1,2,3,4,5,6-hexaone octahydrate(Triquinoyl octahydrate) is a metal-organic framework (MOF).

Cyclobenzaprine (MK130) is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine also possesses antiparasitic activity. Cyclobenzaprine holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases.

CuET, a metabolite of Disulfiram, is a cuproptosis and ferroptosis inducer with anti-tumor activity. CuET interacts directly with polyunsaturated phospholipids to generate free radicals, leading to lipid peroxidation. CuET induces cuproptosis via excessive copper accumulation, leading to lipoylated protein aggregation and iron-sulfur cluster protein loss. CuET induces ferroptosis via a copper-triggered, radical-dependent pathway with limited dependence on iron accumulation, and alters lipid composition to sensitize cells to peroxidative damage. CuET increases intracellular ROS and MDA levels in cancer cells. CuET exhibits anti-tumor activity against non-small cell lung cancer in vitro and in vivo. CuET can be used for the research of cancer, such as non-small cell lung cancer.

CTR/AMYR agonist-1 enantiomer is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 enantiomer can be used for the research of metabolic disease.

CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.

CSP-2503 is a potent and selective 5-HT1A receptor agonist , with an EC50 of 0.15 μM and a Ki of 4.1 nM. CSP-2503 exhibits excellent selectivity over α1-adrenoceptors (Ki > 1000 nM), 5-HT4 receptors, and benzodiazepine receptors. CSP-2503 inhibits cAMP increase in vitro and exhibits anxiolytic activity in vivo. CSP-2503 can be used for the research of anxiety-related disorders.

CRBN ligand-222 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-222 can be linked to a target protein ligand via a linker to form a PROTAC.

CP-467688 is a retinal toxicant with a basic pKa=8.1 and lipophilic clogP=5.0. CP-467688 is promising for research of drug-induced retinopathy.

CP-457493 is an Erlotinib metabolite. CP-457493 can be detected in plasma.

Copanlisib-NH is a PI3Kα/δ ligand. Copanlisib-NH can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC PI3Kα/δ, such as PROTAC PI3Kα/δ degrader-1. Copanlisib-NH can be used in breast cancer research.

Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals.

CN016 is a neuroprotective agent. CN016 inhibits the elevation of pro-inflammatory cytokines G-CSF, GM-CSF and IL-6 induced by Oxaliplatin. CN016 suppresses Paclitaxel-induced inflammatory responses and immune cell infiltration into sensory neurons. CN016 protects neurons from Paclitaxel-induced neurotoxic damage. CN016 protects mice against Oxaliplatin-induced peripheral neuropathy.

Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias.

Clodazon (AW 142446) is an antidepressive agent.

Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC50 of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC50 of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC50 of 29.7 μM.

CK1γ-IN-1 is a non-selective CK1 kinase inhibitor with IC50 values of 780 nM, 570 nM and 990 nM against human CK1γ1, CK1γ2, CK1γ3, respectively. The non-specific binding of CK1γ-IN-1 to multiple kinases enables its application in biological studies of specific CK1γ.

Cizolirtine citrate (E-4018) is an analgesic agent. Cizolirtine citrate has significant analgesic and anti-hyperalgesic action in neuropathic pain models.

Cioteronel is an antiandrogen agent. Cioteronel can be studied in research on androgenetic alopecia.

Ciliatocholate (Ciliatocholic acid) is a nucleoside metabolite.

CI-996 is a potent, selective, orally active angiotensin II (Ang II) type 1 (AT1) receptor antagonist. In rat liver membranes CI-996 displaces specifically bind [125I]Ang II with an IC50 of 0.8 nM. CI-996 has blood pressure-lowering activity.

CI-986 is a dual inhibitor of COX and 5-LOX. CI-986 can prevent the coronary vasoconstriction and the increased production of LTB(4) and LTC(4). CI-986 also has anti-inflammatory and analgesic effects. CI-986 can be used for the researches of inflammation and cardiovascular disease, such as arthritis.

CI-959 is an inhibitor of inflammatory cell activation. CI-959 exhibits anti-inflammatory and anti-allergic activities. CI-959 can inhibit the production of reactive oxygen species by neutrophils, as well as neutrophil adhesion, respiratory burst, and histamine release from mast cells. CI-959 can also inhibit the release of inflammatory mediators such as histamine, leukotrienes, and thromboxane from guinea-pig and human lung tissues, and effectively suppress anti-IgE-induced contractions of human bronchial smooth muscle. CI-959 can be used in the research of inflammatory and allergic diseases, such as asthma.

CHX-3107 is a casein kinase 2 inhibitor .

CHNQD-03301 is an orally active hypoxia-inducible factor-1α (HIF-1α) inhibitor (IC50 = 10.97 nM). CHNQD-03301 promotes the proteasomal degradation of HIF-1α protein, leading to its significant suppression. CHNQD-03301 can reverse HIF accumulation-induced angiogenesis and mitigate the HIF-induced erythrocytosis phenotype in zebrafish models. CHNQD-03301 can be used for the study of colon cancer.

Chlorproethazine hydrochloride is an orally active phenothiazine compound. Chlorproethazine hydrochloride can eliminate spasticity when administered intravenously and also effectively reduce rigidity in decerebrate cats. Chlorproethazine hydrochloride can be used in the research of neurological diseases.

Chenodeoxycholyl-putrescine is a polyamine bile amidate.